• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Potent Influenza A Virus Entry Inhibitors Targeting a Conserved Region of Hemagglutinin

tetano

Editor, Senior Moderator
Biochem Pharmacol. 2017 Jul 31. pii: S0006-2952(17)30511-7. doi: 10.1016/j.bcp.2017.07.023. [Epub ahead of print]
[h=1]Potent Influenza A Virus Entry Inhibitors Targeting a Conserved Region of Hemagglutinin.[/h] Lin D[SUP]1[/SUP], Luo Y[SUP]2[/SUP], Yang G[SUP]3[/SUP], Li F[SUP]3[/SUP], Xie X[SUP]4[/SUP], Chen D[SUP]3[/SUP], He L[SUP]2[/SUP], Wang J[SUP]3[/SUP], Ye C[SUP]3[/SUP], Lu S[SUP]3[/SUP], Lv L[SUP]3[/SUP], Liu S[SUP]5[/SUP], He J[SUP]6[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Influenza A viruses (IAVs) induce acute respiratory disease and cause significant morbidity and mortality throughout the world. With the emergence of drug-resistant viral strains, new and effective anti-IAV drugs with different modes of action are urgently needed. In this study, by conjugating cholesterol to the N-terminus of the short peptide KKWK, a lipopeptide named S-KKWK was created. The anti-IAV test indicated that S-KKWK and its derivatives displayed potent antiviral activities against a broad variety of influenza A viral strains including oseltamivir-resistant strains and clinically relevant isolates with IC[SUB]50[/SUB] values ranging from 0.7 to 3.0 ?M. An extensive mechanistic study showed that these peptides functioned as viral "entry blockers" by inhibiting the conformational rearrangements of HA2 subunit, thereby interrupting the fusion of virus-host cell membranes. Significantly, a computer-aided docking simulation and protein sequence alignment identified conserved residues in the stem region of HA2 as the possible binding site of S-KKWK, which may be employed as a potential drug target for designing anti-IAVs with a broad-spectrum of activity. By targeting this region, a potent anti-IAV agent was subsequently created. In addition, the anti-IAV activity of S-KKWK was assessed by experiments with influenza A virus-infected mice, in which S-KKWK reduced the mortality of infected animals and extended survival time significantly. Overall, in addition to providing a strategy for designing broad-spectrum anti-IAV agents, these results indicate that S-KKWK and its derivatives are prospective candidates for potent antivirals.
Copyright ? 2017. Published by Elsevier Inc.


[h=4]KEYWORDS:[/h] Anti-influenza A viruses; Cholesterol conjugated peptides; Conserved region of hemagglutinin; Virus entry inhibitors

PMID: 28774731 DOI: 10.1016/j.bcp.2017.07.023
 
Back
Top Bottom